Under the constant pressure of pharmaceutical companies, a large number of drugs are withdrawing from the medical insurance catalog

Recently, the provincial medical insurance bureaus are vigorously carrying out the work of calling out the medical insurance catalogue
.
From the current point of view, many provinces and cities, such as Anhui, Guizhou, Zhejiang, Jiangsu, etc.
, have released relevant documents to arrange the specific variety transfer time
.
In this context, many large varieties of pharmaceutical companies are also accelerating their withdrawal from medical insurance
.
Recently, Buchang Pharmaceutical announced that its wholly-owned subsidiary Tonghua Guhong Pharmaceutical Co.
, Ltd.
drug Guhong Injection will withdraw from the Anhui Provincial Medical Insurance Catalogue on December 31, 2022
.
It is understood that Guhong injection is mainly used to treat cerebrovascular diseases such as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism and cerebral hemorrhage in the recovery period, liver disease, neurosurgery, etc.
Can be used for the treatment of coronary heart disease, vasculitis and so on
.
The operating income of this product in Anhui Province in 2020 was 17.
1006 million yuan, accounting for 0.
11% of the company's operating income in 2020
.
In addition to Guhong injection, in recent years, Buchang Pharmaceutical has a number of drugs that have been withdrawn from medical insurance in many places
.
For example, on July 2, 2021, Buchang Pharmaceutical announced to the public that its holding subsidiary Jilin Tiancheng Pharmaceutical Co.
, Ltd.
drug compound cerebroside nodose injection and its wholly-owned subsidiary Tonghua Guhong Pharmaceutical Co.
, Ltd.
drug Guhong injection will be released in this May withdraw from the Yunnan Provincial Medical Insurance Directory
.
Among them, compound cerebropeptide ganglioside injection is used for the treatment of stroke, senile dementia, craniocerebral injury, spinal cord injury and traumatic peripheral nerve injury, and for the treatment of functional disorders caused by brain diseases
.
The drug's revenue in 2020 was 1.
244 billion yuan
.
On December 1, 2021, Buchang Pharmaceutical issued an announcement.
According to the Hubei Provincial Medical Security Bureau's "Notice of the Provincial Medical Security Bureau on Digesting Supplementary Drugs for Hubei Provincial Medical Insurance" E Medical Insurance Fa (2021) No.
31, the company's holding subsidiary Jilin Tiancheng Pharmaceutical Co.
, Ltd.
's drug compound cerebropeptide ganglioside injection has also been withdrawn from the Hubei Provincial Medical Insurance Catalog
.
The data show that compound cerebropeptide ganglioside injection is used for the treatment of stroke, senile dementia, craniocerebral injury, spinal cord injury and traumatic peripheral nerve injury, and for the treatment of dysfunction caused by brain diseases
.
The industry believes that it is not uncommon for drugs to withdraw from the medical insurance catalogs of various provinces
.
However, in recent years, especially last year, a number of pharmaceutical companies have collectively withdrawn from the multi-provincial medical insurance catalogue
.
For example, Yunnan Baiyao has withdrawn from the Heilongjiang market last year, namely, "Muxiang Jieda Rheumatism Ointment", "Gongmaozhike Granules", "Gongxuening Capsules" and "Chenxianglu Bailu Tablets"
.
The reason given by Yunnan Baiyao for withdrawing from the network is that the price of raw materials cannot be supplied
.
There are five drugs that Sinopharm has withdrawn from the network in Heilongjiang, namely lysine 0.
25g, lysine 0.
5g, lysine 0.
9g, clindamycin 0.
45g, and spectinomycin 2.
0g
.
In the column of reasons for withdrawing from the network, Sinopharm Uniformly filled in as "rising raw materials and rising costs"
.
On the whole, a series of medical reforms have brought huge pressure on domestic production enterprises.
A series of reasons such as environmental protection, logistics, management, and labor costs have become the main reasons for pharmaceutical companies to withdraw their products from medical insurance
.
However, the withdrawal of these drugs will obviously not cause problems in the medical insurance of ordinary people
.
Therefore, pharmaceutical companies can no longer gain a foothold in the market only through marketing and price wars
.
In the future, pharmaceutical companies will need to find ways to strengthen their cost control capabilities, build more core varieties, accelerate the increase in market share, and seize the market with cost advantages in order to have more opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.